Publications ON-BOARD™ ONM-412 ONM-501 Pegsitacianine ONM-501 Brad Good 6/2/24 ONM-501 Brad Good 6/2/24 A Phase 1 Dose-escalation and Expansion Study of an Intratumorally Administered Dual STING Agonist (ONM-501) Alone and in Combination with Cemiplimab Read More ONM-501 Brad Good 4/18/23 ONM-501 Brad Good 4/18/23 ONM-501, a dual-activating polyvalent STING agonist, enhances tumor retention and demonstrates favorable preclinical safety profile Read More ONM-501 Brad Good 11/10/22 ONM-501 Brad Good 11/10/22 A polyvalent STING agonist, exhibits anti-tumor efficacy with increased tumor T-cell infiltration in mice and is well tolerated in rats and non-human primates Read More ONM-501 Brad Good 4/13/22 ONM-501 Brad Good 4/13/22 ONM-501 – A polyvalent STING agonist for oncology immunotherapy Read More ONM-501 Brad Good 2/8/21 ONM-501 Brad Good 2/8/21 Prolonged activation of innate immune pathways by a polyvalent STING agonist Read More
ONM-501 Brad Good 6/2/24 ONM-501 Brad Good 6/2/24 A Phase 1 Dose-escalation and Expansion Study of an Intratumorally Administered Dual STING Agonist (ONM-501) Alone and in Combination with Cemiplimab Read More
ONM-501 Brad Good 4/18/23 ONM-501 Brad Good 4/18/23 ONM-501, a dual-activating polyvalent STING agonist, enhances tumor retention and demonstrates favorable preclinical safety profile Read More
ONM-501 Brad Good 11/10/22 ONM-501 Brad Good 11/10/22 A polyvalent STING agonist, exhibits anti-tumor efficacy with increased tumor T-cell infiltration in mice and is well tolerated in rats and non-human primates Read More
ONM-501 Brad Good 4/13/22 ONM-501 Brad Good 4/13/22 ONM-501 – A polyvalent STING agonist for oncology immunotherapy Read More
ONM-501 Brad Good 2/8/21 ONM-501 Brad Good 2/8/21 Prolonged activation of innate immune pathways by a polyvalent STING agonist Read More
